Generic bashing back in vogue?
This article was originally published in Scrip
Executive Summary
At a time when even biosimilars have been gaining acceptance among doctors as safe and effective alternatives to originator biologicals, it is astonishing that a company of Sanofi’s stature should have been caught casting doubt on the safety and efficacy of generics.